Influx Healthtech IPO Details

SME NSE

Influx Healthtech IPO Summary

Influx Healthtech IPO DRHP (Draft Red Herring Prospectus) has been Offer Document Withdrawn.

Influx Healthtech IPO total issue size comprises 50,00,400 shares . This includes a fresh issue of 50,00,400 shares . Pre-issue shareholding stands at 1,81,50,000, which will increase to 2,31,50,400 post-issue.

Influx Healthtech IPO carries a ₹0 (0%) GMP, reflecting investor sentiment.

The Lead Managers for Influx Healthtech IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Rarever Financial Advisors Pvt Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.

For detailed information, Refer to the Influx Healthtech Limited DRHP.

Influx Healthtech IPO Details

Open Date

Close Date

Listing Date

Issue Price

₹0 - ₹0

Face Value

₹10 per share

Lot Size

0 Shares

GMP

₹0

Issue Type

IPO

Listing On

NSE

Type

Book Built Issue

Pre-issue Shareholding

1,81,50,000 shares

Post-issue Shareholding

2,31,50,400 shares

Total Issue Size

50,00,400 shares

Fresh Issue

50,00,400 shares

Offer for Sale

DRHP Status

Offer Document Withdrawn

Influx Healthtech IPO Lot Size

Application	Lots	Shares	Amount
To be announced

Influx Healthtech IPO Reservation

Promoter Holding

Pre Issue:

99.85%

Post Issue:

Promoter Names:

Mr. Munir Abdul Ganee Chandniwala, Mrs. Shirin Munir Ahmed Chandniwala, Mr. Abdul Ganee Abdul Rasul Chandniwala

Documents

DRHP

Influx Healthtech IPO DRHP

Influx Healthtech IPO Valuations

ROE49.06%

ROCE65.43%

RONW49.06%

PAT MARGIN11.22

Influx Healthtech Financial Information

Period Ended	30 Nov 2024	31 Mar 2024	31 Mar 2023	31 Mar 2022
Assets	56.97	41.1	28.3	17.59
Revenue	63.29	100.1	76.07	59.2
Profit After Tax	8.05	11.22	7.2	4.43
Net Worth	30.92	22.87	11.65	4.46
Reserves and Surplus	12.77	22.85	11.63	4.43
Total Borrowing	0.27	0.29	0.75	0.57
Amount in ₹ Crore

About Influx Healthtech IPO

Incorporated in September 2020, Influx Healthtech Limited is a healthcare-focused company specialising in contract manufacturing. The company is a reliable CDMO, providing specialized services to clients in multiple industries.

The company has three manufacturing facilities in Thane, Maharashtra, each covering an area of 9,676 square feet, 13,000 square feet, and 14,000 square feet, respectively.

The product portfolio of the company consists of the following

Tablets, Capsules, and Powders
Liquid Orals and Softgels
Lozenges, Jellies, and Gummies
Oral Dispersible Films (ODFs)
Effervescent Tablets and Liquid-Fill Capsules
Candies and Gym/Sports Supplements
Skin Care and Body Care Products
Hair Care and Beard Care Solutions
Face Masks and Soaps.
Ayurvedic / Herbal formulations
Veterinary Feed Supplements
Homecare solutions

The Company aids Nutraceutical and Cosmetic firms with product development and manufacturing. It offers end-to-end services, including development, production, and regulatory support, enabling clients to focus on formulation and commercialization.

As of March 31, 2024, key clients include Bling Brands, Evoq Ventures, HSHS Nutraceuticals, Bruder Life Science, and Bigflex Lifescience.

Strength Of Influx Healthtech IPO

To be announced

Risk Of Influx Healthtech IPO

To be announced

Objectives Influx Healthtech IPO

Funding capital expenditure requirements for setting up of manufacturing facility for the Nutraceutical Division.
Funding capital expenditure requirements for setting up of manufacturing facility for Veterinary Food Division.
Purchase of Machineries for Homecare and Cosmetic Division.
General Corporate Purposes.

Company Contact Details

Influx Healthtech Limited
109, Ghanshyam Enclave Premises Co-op
Soc Plot No. 856, Laljipada
Kandivali West, Mumbai - 400067
Phone: +91 7045997809
Email: cs@influxhealthtech.com
Website: https://influxhealthtech.com/

Registrar Contact Details

Name:

Maashitla Securities Pvt Ltd

Phone:

+91-11-45121795, +91-11-45121796

Email:

ipo@maashitla.com

Website:

https://maashitla.com/allotment-status/public-issues

Lead Mangers

Market Maker

To be announced

Influx Healthtech FAQs

The Influx Healthtech IPO is a SME public issue comprising 5000400 equity shares with a face value of ₹10 each, aggregating to a total issue size of . The issue price has been fixed at ₹0 per equity share, and the minimum application size is 0 shares.

The IPO opens for subscription on TBA, and closes on TBA.

Maashitla Securities Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the NSE

The Influx Healthtech IPO opens on TBA.

Influx Healthtech IPO lot size is 0, and the minimum amount required for application is ₹0.

You may apply for the Influx Healthtech IPO online by using either the UPI or ASBA payment method. The ASBA facility is available through the net banking platform of your respective bank. The UPI-based IPO application option is typically provided by brokers that do not offer banking services. For detailed guidance on the online IPO application process, please refer to the procedures outlined by Zerodha, Groww, Upstox, 5Paisa, Paytm Money, Fyers, Alice Blue, Nuvama, HDFC Bank, ICICI Direct, Kotak Securities, Axis Direct, and SBI Bank.

The Basis of Allotment for the Influx Healthtech IPO is scheduled to be finalized on TBA. Subsequently, the shares allotted will be credited to investors’ demat accounts by TBA. Investors are advised to regularly check the Influx Healthtech IPO allotment status for updates.

The listing date for the Influx Healthtech IPO has not yet been officially announced. However, the tentative listing date is scheduled for TBA.

Influx Healthtech IPO Grey Market Premium (GMP) refers to the unofficial price at which the company’s IPO shares are traded in the grey market prior to their listing on the stock exchange. The GMP serves as an indicator of investor demand, expected listing gains, and the overall market sentiment toward the IPO.

As of now, the current GMP stands at TBA.